Pulse Biosciences Inc. expects to begin a pilot study of its PulseTx nano-pulse system for immunoncology applications within a year, building on preclinical research showing that very short pulses of electricity can both induce cell death without residual tissue damage and induce an immunologic response that prevents cancer from coming back.
"I think the year ahead was really about clinical development," Darrin Uecker, CEO and president of Pulse Biosciences, told Medtech Insight. "We spent the last 12 to 18 months...